high blood pressure Hypertension
Conditions
Interventions
The brachial artery will be cannulated (20 gauge catheter) for infusion of
bevacizumab 144 microgram/dl forearm volume ( 15 minutes).
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-50 years old 2. Male 3. Results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges. 4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
Exclusion criteria
Exclusion criteria: 1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients. 2. History of or current abuse of drugs, alcohol or solvents. 3. History of malignant disease. 4. First degree relatives with a history of cancer before the age of 50 5. First degree relatives with a history of premature cardiovascular disease before the age of 50 6. Current use of medication. 7. Hypertension ( systole >140mmHG, diastole >90mmHg) 8. Diabetes mellitus 9. Smoking 10. Any clinically relevant abnormality on ECG. 11. A history of thrombosis or first degree family members with a history of recurrent thrombosis 12. Inability to understand the nature and extent of the trial and the procedures required. 14. Previous participation in a study with bevacizumab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The forearm vasomotor response to increasing doses of intra-arterially administered acetylcholine (two doses each) before and during administration of bevacizumab, expressed as percentage change in forearm blood flow ratio (flow infused arm/flow control arm) from baseline. | — |
Countries
Netherlands
Outcome results
None listed